Claims
- 1. A method of enriching for dendritic cells from a mixture of cells comprising contacting the mixture of cells with an antigen-binding fragment specific for CD141 and selecting the cells that are CD141+, thereby producing a dendritic cell-enriched composition.
- 2. The method of claim 1, wherein the antigen-binding fragment is detectably labeled.
- 3. The method of claim 2, wherein said selection is flow cytometric selection or magnetic particle separation.
- 4. The method of claim 1 wherein the dendritic cells are CD1c−CD11c+CD123−.
- 5. The method of claim 1 wherein the mixture of cells is blood or a blood fraction.
- 6. The method of claim 1 wherein the blood or blood fraction is from peripheral blood or umbilical cord blood.
- 7. The method of claim 6 wherein the blood fraction is peripheral blood mononuclear cells, perpheral blood lymphocytes or from a leukopheresis harvest.
- 8. The method of claim 6 wherein the blood or blood fraction is cultured.
- 9. The method of claim 1 where the mixture of cells comprises cells from bone marrow.
- 10. The method of claim 5 wherein the blood or blood fraction is from a subject treated with a agent that increases the number of dendritic cells resident in peripheral blood.
- 11. The method of claim 10 wherein the agent is Flt3-Ligand or G-CSF.
- 12. The method of claim 1, further comprising depletion of non-dendritic cell types from the mixture.
- 13. A dendritic cell-enriched composition obtained by the method of claim 1 or obtained by culturing cells obtained by the method of claim 1.
- 14. A composition that comprises at least about 5% CD1c−CD11c+CD123− dendritic cells.
- 15. The composition of claim 14 that comprises at least about 30% dendritic cells.
- 16. A composition of claim 14 that comprises at least about 50% CD1c−CD11c+CD123− dendritic cells.
- 17. A method of modulating cytokine production by a dendritic cell comprising contacting the composition of claim 13 with an agent that modulates dendritic cell cytokine production.
- 18. The method of claim 17 wherein the agent is IL-3.
- 19. A method of distinguishing a subpopulation of dendritic cells from at least one other cell in a population of peripheral blood cells comprising contacting the population with a CD141 binding fragment and detecting the cells to which the binding fragment binds.
- 20. The method of claim 19 further comprising contacting said population with at least one antibody with specificity for a dendritic cell lineage marker or with specificity for a non-dendritic cell lineage marker and detecting the cells to which the antibody binds.
- 21. The method of claim 20, wherein the CD141 binding fragment is detectably labeled.
- 22. The method of claim 21, wherein said label is fluorescent.
- 23. The method of claim 22, wherein said detection is by flow cytometry.
- 24. A method of generating an immune response specific for an antigen in a subject, comprising administering to a subject in need thereof dendritic cells from a composition of claim 14, wherein said dendritic cells are presenting the antigen as a MHC-antigen complex.
- 25. The method according to claim 24, wherein said dendritic cells are genetically modified to express the antigen.
- 26. The method of claim 24 wherein the immune response is a T cell response.
- 27. A method of monitoring production of dendritic cell cytokines comprising culturing a composition of claim 14 and monitoring cytokines produced by dendritic cells in the composition.
- 28. A method of assaying for the effect of an agent on dendritic cell cytokine production comprising contacting a composition of claim 14 with the agent and monitoring the effect of the agent on cytokines produced by dendritic cells in the composition.
- 29. A method of depleting dendritic cells from a population of peripheral blood mononuclear cells comprising contacting said population with an an antigen-binding fragment and removing cells that are CD141+.
- 30. A method of inhibiting an interaction of a dendritic cell with a ligand that binds CD141 on the dendritic cell surface comprising contacting the dendritic cell with a CD141 binding fragment or reducing the expression of CD141 on the dendritic cell surface.
- 31. A method of inhibiting an interaction of a dendritic cell and a T cell comprising contacting the dendritic cell with a CD141 binding fragment or reducing the expression of CD141 on the dendritic cell surface.
- 32. The method of claim 31 that is a method of treating inflammation comprising administering to a subject in need thereof an amount of an agent that inhibits the interaction of CD141 and a T cell or reduces the expression of CD141 on the surface of dendritic cells.
- 33. The method according to claim 31 wherein the agent is administered in vivo or in vitro.
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application claims benefit of U.S. provisional application 60/291,561, filed May 17, 2001, the entire contents of which is incorporated by reference herein.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60291561 |
May 2001 |
US |